CD30: From basic research to cancer therapy

Hiromi Muta, Eckhard R. Podack

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas the potent clinical activity of Brentuximab vedotin in Hodgkin's lymphoma and anaplastic large-cell lymphoma was greeted with great enthusiasm by oncologists as it provided a new treatment modality for these diseases. In this review, we will describe how we obtained the hybridoma by pursuing a basic research experiment unrelated to CD30. I will also review what we know about the normal biological functions of CD30 that were studied primarily in murine models of disease but also in patients the picture emerging is that one of the primary functions of CD30 is the control of memory cells providing costimulation and trafficking information or inducing apoptosis in a microenvironment and cytokine milieu-dependent manner.

Original languageEnglish
Pages (from-to)151-158
Number of pages8
JournalImmunologic Research
Volume57
Issue number1-3
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Anaplastic Large-Cell Lymphoma
Hybridomas
Hodgkin Disease
Research
Lymphoma
Neoplasms
Apoptosis
Cytokines
Therapeutics
Pharmaceutical Preparations
cAC10-vcMMAE
Oncologists

Keywords

  • ALCL
  • Asthma
  • CCR7
  • Colitis
  • Hodgkin
  • Memory
  • Mucosal immunity
  • Th17

ASJC Scopus subject areas

  • Immunology

Cite this

CD30 : From basic research to cancer therapy. / Muta, Hiromi; Podack, Eckhard R.

In: Immunologic Research, Vol. 57, No. 1-3, 01.12.2013, p. 151-158.

Research output: Contribution to journalArticle

Muta, Hiromi ; Podack, Eckhard R. / CD30 : From basic research to cancer therapy. In: Immunologic Research. 2013 ; Vol. 57, No. 1-3. pp. 151-158.
@article{c528c3bcda024da29691bb27533e0219,
title = "CD30: From basic research to cancer therapy",
abstract = "The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas the potent clinical activity of Brentuximab vedotin in Hodgkin's lymphoma and anaplastic large-cell lymphoma was greeted with great enthusiasm by oncologists as it provided a new treatment modality for these diseases. In this review, we will describe how we obtained the hybridoma by pursuing a basic research experiment unrelated to CD30. I will also review what we know about the normal biological functions of CD30 that were studied primarily in murine models of disease but also in patients the picture emerging is that one of the primary functions of CD30 is the control of memory cells providing costimulation and trafficking information or inducing apoptosis in a microenvironment and cytokine milieu-dependent manner.",
keywords = "ALCL, Asthma, CCR7, Colitis, Hodgkin, Memory, Mucosal immunity, Th17",
author = "Hiromi Muta and Podack, {Eckhard R.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/s12026-013-8464-1",
language = "English",
volume = "57",
pages = "151--158",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - CD30

T2 - From basic research to cancer therapy

AU - Muta, Hiromi

AU - Podack, Eckhard R.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas the potent clinical activity of Brentuximab vedotin in Hodgkin's lymphoma and anaplastic large-cell lymphoma was greeted with great enthusiasm by oncologists as it provided a new treatment modality for these diseases. In this review, we will describe how we obtained the hybridoma by pursuing a basic research experiment unrelated to CD30. I will also review what we know about the normal biological functions of CD30 that were studied primarily in murine models of disease but also in patients the picture emerging is that one of the primary functions of CD30 is the control of memory cells providing costimulation and trafficking information or inducing apoptosis in a microenvironment and cytokine milieu-dependent manner.

AB - The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas the potent clinical activity of Brentuximab vedotin in Hodgkin's lymphoma and anaplastic large-cell lymphoma was greeted with great enthusiasm by oncologists as it provided a new treatment modality for these diseases. In this review, we will describe how we obtained the hybridoma by pursuing a basic research experiment unrelated to CD30. I will also review what we know about the normal biological functions of CD30 that were studied primarily in murine models of disease but also in patients the picture emerging is that one of the primary functions of CD30 is the control of memory cells providing costimulation and trafficking information or inducing apoptosis in a microenvironment and cytokine milieu-dependent manner.

KW - ALCL

KW - Asthma

KW - CCR7

KW - Colitis

KW - Hodgkin

KW - Memory

KW - Mucosal immunity

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=84891490519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891490519&partnerID=8YFLogxK

U2 - 10.1007/s12026-013-8464-1

DO - 10.1007/s12026-013-8464-1

M3 - Article

C2 - 24233555

AN - SCOPUS:84891490519

VL - 57

SP - 151

EP - 158

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 1-3

ER -